Ftse Mib
33.987,67
-0,35%
DAX
18.475,45
0,12%
S&P 500
5.567,19
1,06%
NASDAQ
18.352,76
0,90%
Bitcoin
57.622,00
-1,16%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lisata Therapeutics Inc (LSTA) Lisata Therapeutics Inc (LSTA) Notizie

LSTA

Lisata Therapeutics (LSTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LSTA
DataOraFonteTitoloSimboloCompagnia
13/06/202414:30GlobeNewswire Inc.Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialNASDAQ:LSTALisata Therapeutics Inc
28/05/202414:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
20/05/202414:30GlobeNewswire Inc.Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerNASDAQ:LSTALisata Therapeutics Inc
10/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LSTALisata Therapeutics Inc
09/05/202422:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LSTALisata Therapeutics Inc
09/05/202422:05GlobeNewswire Inc.Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
08/05/202414:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
02/05/202414:00GlobeNewswire Inc.Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024NASDAQ:LSTALisata Therapeutics Inc
23/04/202413:30GlobeNewswire Inc.Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
09/04/202414:30GlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
03/04/202414:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
21/03/202413:00GlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
04/03/202414:00GlobeNewswire Inc.Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰNASDAQ:LSTALisata Therapeutics Inc
29/02/202422:05GlobeNewswire Inc.Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
22/02/202414:00GlobeNewswire Inc.Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern TimeNASDAQ:LSTALisata Therapeutics Inc
20/02/202414:00GlobeNewswire Inc.Lisata Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
18/01/202414:30GlobeNewswire Inc.Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto RicoNASDAQ:LSTALisata Therapeutics Inc
17/01/202414:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma MultiformeNASDAQ:LSTALisata Therapeutics Inc
04/01/202414:00GlobeNewswire Inc.Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care TherapyNASDAQ:LSTALisata Therapeutics Inc
12/12/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
28/11/202322:05GlobeNewswire Inc.Lisata Therapeutics to Present at NobleCon19 Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
09/11/202322:05GlobeNewswire Inc.Lisata Therapeutics Announces Participation in Upcoming Conferences in NovemberNASDAQ:LSTALisata Therapeutics Inc
02/11/202321:05GlobeNewswire Inc.Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
26/10/202314:00GlobeNewswire Inc.Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern TimeNASDAQ:LSTALisata Therapeutics Inc
24/10/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating PeptideNASDAQ:LSTALisata Therapeutics Inc
17/10/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer NASDAQ:LSTALisata Therapeutics Inc
28/09/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces Participation in Upcoming Conferences in OctoberNASDAQ:LSTALisata Therapeutics Inc
20/09/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces Participation in InfoSec World 2023NASDAQ:LSTALisata Therapeutics Inc
12/09/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid TumorsNASDAQ:LSTALisata Therapeutics Inc
06/09/202314:00GlobeNewswire Inc.Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LSTA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
AMP
Amplifon
BIT
STMMI
ST Microelectronics
BIT
FCTAAW
Fincantieri
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
BPE
Bper Banca
BIT
FCT
Fincantieri
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network